This review highlights recent advances in our understanding of the frequency and nature of alloreactivity among memory T-cell populations, and discusses recent successes in experimentally targeting these populations in order to prolong graft survival.
Introduction T-cell memory is a hallmark of adaptive immunity and plays a critical role in providing protective immunity to transplant recipients, who may lose the ability to mount de novo cellular immune responses while on immunosuppression. However, many studies over the last decades revealed the double-edged sword of memory T cells; that is, while providing protective immunity against the panoply of pathogens encountered on a daily basis, these cells may also pose a potent barrier to the attenuation of donorspecific immune responses and the induction of tolerance or a tolerant-like state. Herein, we discuss recent advances in our understanding of the frequency and nature of alloreactivity among memory T-cell populations, and advances in therapeutically targeting these populations in the hope of prolonging graft survival following transplantation.
Evidence for the existence of alloreactive T cells among memory
Perhaps the first and most fundamental question when contemplating the potential barrier posed by alloreactive memory T cells is to consider the evidence that alloreactivity exists among memory T cells. The issue of whether alloreactive T-cell precursor frequencies are higher, lower, or equivalent among memory T-cell populations as compared with naïve T cells has been debated for at least 2 decades [1, 2] . Early experiments addressed the alloreactivity of cord blood-derived T-cell populations, which would putatively contain little to no memory T cells [2] . During the last year however, this issue has been largely put to rest, mainly with the publication of a study by Macedo et al. [3 ] , which analyzed the frequencies of alloreactive T cells in naïve (CD45RO À CD62L þ ), central memory (CD45RO þ CD62L þ ), effector memory (CD45RO þ CD62L À ), and terminal effector memory (CD4RO À CD62L À ) compartments, and found roughly equal frequencies of alloreactivity among all four compartments. Importantly, however, differences in the ways in which alloreactivity manifested in these different T-cell populations were noted. For example, in the CD8 þ T-cell compartment, naïve T cells exhibited increased proliferation in response to allostimulation as compared with effector memory T cells (T EM ), whereas T EM exhibited increased granzyme B/perforin expression as compared with naïve T cells in response to alloantigen [3 ] . Thus, these data highlight that although the overall frequency of alloreactive T cells in memory vs. naïve T-cell compartments may be similar, the behavior of these alloreactive cells in vivo may be quite distinct, depending on their differentiation status.
Advances in our understanding in the generation of donor-reactive T-cell memory
How do donor-reactive memory T cells arise in a previously untransplanted recipient? Existing ideas suggested that donor-reactive memory T cells could be generated via pregnancy, exposure to environmental pathogens, and frequent blood transfusions [4, 5] . A recent report has conclusively demonstrated the latter phenomenon. Specifically, Patel et al. [6] found that immunity generated against transfused platelets, even across only minor histocompatibility antigens, was sufficient to induce rejection following subsequent bone marrow transplantation in murine recipients [6] . These data indicate that patients receiving even leuko-reduced platelet products may be at an increased risk for memory T-cell-mediated graft rejection following bone marrow transplantation; however, further experiments examining the barriers posed by transfusion-derived minor antigens in experimental models of solid-organ transplantation are needed.
As mentioned above, donor-reactive memory T cells have also been purported to arise via exposure to environmental pathogens. Evidence for this exists from both human and mouse models. For example, studies by Burrows et al. [7] [8] [9] demonstrated that T-cells specific for Epstein-Barr virus nuclear antigen-3A (EBNA-3A) restricted by human leukocyte antigen (HLA)-B8 were cross-reactive with HLA-B44 (putatively presenting a self-peptide). Earlier studies showed that CD4 þ T cells specific for tetanus toxoid in the context of HLA-DR3 were cross-reactive with HLA-DR4 [10] , and a T cell specific for HSV-VP13/14 presented by A2 has been shown to also cross-react with HLA-B44 [11] . Thus, scattered throughout the literature are examples of specific donor-recipient pairs eliciting cross-reactivity between pathogen-specific and alloreactive T-cell populations. But just how common is this phenomenon? This year, a new study by Heemskerk and colleagues suggests that it is in fact quite common, perhaps much more so than originally thought. In this elegant series of experiments, Amir et al. [12 ] analyzed pathogen-specific T-cell lines and clones against a panel of HLA-typed target cells, and found that fully 80% of T-cell lines and 45% of pathogen-specific T-cell clones exhibited alloreactivity. For the pathogen-specific T-cell clones, this cross-reactivity was usually confined to a single HLA molecule. Importantly, T-cell receptor (TCR) gene transfer experiments demonstrated that the pathogen and alloreactivity was conferred by a single TCR, thus confirming cross-reactivity at the molecular level [12 ] . These results have important implications for the field of transplantation, in which they indicate that the phenomenon of heterologous immunity is perhaps much more common than originally anticipated. Thus, the question becomes not just whether donor-reactive memory T cells exist in a given recipient, but rather to what degree their frequency, phenotype, and functionality determines the relative barrier posed by donor-reactive memory T-cell populations present in a given individual.
On the nature of T-cell allorecognition via molecular mimicry
Although the existence of heterologous immunity in transplantation has been recognized at the cellular level for more than a decade [13] , the molecular mechanisms underlying this phenomenon are just beginning to be elucidated. Heterologous immunity as a broader term refers to the observation that one stimulus can lead to an immune response, either cell-mediated or humoral, which affects the response to a second, distinct stimulus [14] . For T-cell response, one could conceive of at least two possible mechanisms that could contribute to this observation: bystander activation and molecular mimicry. Recently, important experimental evidence supporting the existence of molecular mimicry as an underlying cause of alloreactivity among heterologous immune responses has emerged. For instance, Felix et al. [15] published a seminal study analyzing the molecular basis underlying the specificity of alloreactive T cells for peptide: major histocompatibility complex (MHC), and found that alloreactive T cells have the ability to respond to multiple, distinct peptide epitopes that share no sequence homology. Thus, this work demonstrated that alloreactive T cells are in fact 'poly-specific' and may have the ability to recognize many unrelated peptide sequences [16] . These conclusions were extended by the findings of McDonald et al. [17 ] , who reported on the molecular mechanisms underlying the observed crossreactivity of EBV-EBNA3A/HLA-B08 restricted TCR with HLA-B44 molecules. The results of their analyses suggested that dual recognition of unrelated cognate and allogeneic peptide:MHC complexes by a single TCR involved binding modes that were almost identical.
Interestingly, only following TCR ligation were the viral and allopeptides forced into this identical conformation, suggesting an induced-fit mechanism of TCR recognition in these instances [17 ,18] . These seminal studies have therefore definitively demonstrated that heterologous immunity between pathogen-derived and transplant antigens can function at the level of molecular mimicry.
Cross-reactive allospecific memory T-cell repertoire is likely to be more focused than the naïve alloreactive T-cell repertoire Although alloreactivity is equally present in naïve and memory T-cell compartments, the spectrum of specificities within these repertoires is likely to be quite different. Owing to the restricted TCR repertoire of pathogenspecific memory T cells [19, 20] , the alloreactive T-cell repertoire among memory is likely to be confined to fewer discrete TCR clones. However, the frequency of any given clone is much higher within the memory pool as compared with the naïve T-cell repertoire. Thus, given T-cell clones within the memory T-cell pool are likely to be responding at higher frequency than given clones within the naïve T-cell pool. Because high T-cell precursor frequency is known to constitute a barrier to longterm graft survival induced via costimulation blockade [21] [22] [23] , this may be another method by which donorreactive memory T cells constitute a barrier to tolerance induction.
Stimulation history profoundly impacts antigen-specific memory T-cell quantity, quality, and recall requirements
In recent years, it has become increasingly apparent that a large degree of heterogeneity exists among memory T cells in mouse and man. For example, many groups now have characterized the existence of central memory T cells vs. T EM which express different homing receptors that allow them to traffic to the lymphoid organs or peripheral tissues, respectively [24] . These subsets are therefore thought to be responsible for the initiation of recall responses and the surveillance of peripheral tissue sites for invading pathogens, respectively.
The functional phenotypes of memory cells can be influenced by a variety of different factors. Current thinking holds that the route of exposure, dose, replication rate, recurrence, and tropism of the infectious challenge may impact qualitative aspects of memory T-cell development [25] . For example, there is evidence that repeated exposure to a given antigen results not only in increased quantity of antigen-specific memory T cells, but also in altered quality in which the cells became increasingly T EM -like [25] . Therefore, donor-reactive memory T cells that are cross-reactive to antigens presented by recurrent infections, such as the common cold, might be present at a higher precursor frequency and be more likely to exhibit a T EM phenotype than donor-reactive memory T cells generated via exposure to a single infection. Are these cells differentially distributed within the body? Are they mobile or sessile? Do they have distinct homing molecules and recirculation patterns? Do they differ with regard to expression of costimulatory and adhesion molecules? Do they possess altered cytokine or cytolytic function? These questions remain to be answered.
Likewise, donor-reactive memory T cells generated following a latent viral infection, such as a herpesvirus infection, might also possess unique phenotypes and functional characteristics. This is likely owing to the fact that, unlike acute infections (measles, influenza) where virus is cleared, latent or persistent infections such as EBV, cytomegalovirus and the polyomaviruses maintain reservoirs of virus within host cells that can periodically reactivate and cause recurrent clinical disease, resulting in populations of persistently activated, viral-specific memory T cells that possess a predominantly T EM phenotype [26] . Because of this recurring antigen exposure and T EM phenotype, these cells may exhibit altered trafficking patterns, obviate the need for initiation of a recall response in secondary lymphoid tissues [27] , and demonstrate increased resistance to both toleranceinduction strategies [28] [29] [30] and common immunosuppressive agents [31] .
Thus, understanding the relative barrier posed by different subsets of cells within these heterogeneous populations, particularly in terms of resistance to new costimulation blockade-based therapies for transplantation, remains an important goal.
Effector mechanisms used by memory T cells to mediate rejection
As discussed above, it is likely not just the presence of donor-reactive memory T cells, but their functional phenotypes, that likely determine the potency of the relative barrier they pose to transplantation tolerance induction. Evidence characterizing the varied subsets of memory T cells is mounting and it is becoming increasingly clear that these cells may mediate their alloreactivity via different effector functions [3 ].
For example, effector memory T cells are poised in peripheral tissues, with the potential to rapidly respond and infiltrate allografts within 12-24 h [32] . It was previously unknown as to whether these cells remain static residents of peripheral tissues or continuously recirculate throughout peripheral tissues, and a study published this year now suggests that they in fact recirculate to peripheral tissues and are not static [33] . This finding potentially explains the fact that memory T cells are able to infiltrate transplants so quickly and also suggests that tissueresident effector memory T cells could encounter monoclonal antibodies or other therapeutics in the bloodstream, and suggests that achieving high levels of therapeutics in peripheral tissues may not be necessary in order for these reagents to be effective against memory T cells which home there.
Memory T cells are also heterogeneous with regard to their cytokine producing capabilities. Studies of pathogen-specific immune responses and vaccine development first suggested that multicytokine producing cells might be more effective in providing protection from reinfection than single cytokine producers [34] . However, it was not known whether this was also true during memory T-cell-mediated rejection of transplanted tissue. In 2009, Weaver et al. [35 ] published a study examining the cytokine producing potential of different memory T-cell subsets and found that those T cells that formed the most potent barrier to long-term graft survival (CD2 hi T EM cells) were also multicytokine producing effector cells. In addition, these cells showed evidence of cytolytic function in that they expressed the cytolytic effector molecule granzyme and showed evidence of degranulation in vitro [35 ] . Thus, possessing a spectrum of effector functions, each of which could contribute to graft destruction, may determine the relative potency of a given population of memory T cells with regard to their ability to mediate graft rejection.
Potential strategies for attenuation of donor-reactive memory T-cell responses
Although a few studies have pointed to an increased risk of rejection in calcineurin inhibitor-treated recipients possessing an initial high frequency of donor-reactive memory T cells, it is likely that as a general rule calcineurin inhibitors may effectively inhibit the reactivation and effector function of memory T cells [31] . However, in order to improve the side effect profile of immunosuppressive regimens, many investigators over the past 15 years have contributed to the development of belatacept [36] , a second-generation CD28 blocker that has shown immense promise in recent clinical trials [37,38 ,39 ] . For example, in a phase III multicenter clinical trial in renal transplantation, patients treated with belatacept exhibited reduced nephrotoxicity, reduced hyperlipidemia, and a decrease in cardiovascular events as compared with the control group, which received a standard cyclosporine-based immunosuppressive regimen [38 ] . Although these results were certainly promising, this study also revealed that belatacept-treated patients receiving the moderate intensity-dosing regimen exhibited a significant increase in both frequency and severity of acute rejection episodes [38 ] . From studies by many groups in murine models, it is clear that the preexistence of donor-reactive memory T cells is a potent barrier to long-term graft survival induced by costimulation blockade [28, 40] . Thus, it is interesting to speculate that the preexistence of donor-reactive memory in some patients may be one risk factor contributing to higher incidence and severity of acute rejection following costimulation blockade-based therapy. Thus, as use of more selective immunosuppressive therapies such as the CD28 costimulation blockers is increased clinically, the need to simultaneously attenuate donor-reactive memory T-cell responses by targeting memory cell-specific pathways becomes more pressing.
Over the last year, several such novel pathways have been suggested in the literature. First, as mentioned above, Weaver et al. [35 ] observed the ability of CD2 hi T EM cells to mediate costimulation blockade-resistant rejection, and targeted these cells using the CD2 blocker LFA-3-Ig (alefacept) in a nonhuman primate model of renal transplantation. Blockade of CD2, when used as part of a regimen consisting also of CTLA-4 Ig (CD28 blockade) and sirolimus (mTOR blockade), resulted in renal allograft survival beyond the period of treatment (>90 days) in five out of eight rhesus macaques [35 ] . These results suggested that alefacept, which is currently Food and Drug Administration-approved for use in plaque psoriasis, might be an appropriate adjunct therapy for use in combination with CD28 blockers such as belatacept.
As discussed above, memory T cells are known to rapidly traffic into grafts and mediate rejection by exacting effector functions and recruiting in other inflammatory mediators. Thus, one potential strategy to limit their pathogenicity might be to block the ability of memory T cells to migrate into the transplanted tissue. Setoguchi et al. [41] demonstrated that treatment with anti-lymphocyte function-associated antigen 1 (LFA-1) reduced the early infiltration of memory T cells into donor tissue, and we have shown that anti-LFA-1 mAb was effective in inhibiting donor-reactive memory T-cell responses when combined with traditional costimulation blockade in murine models [42] . Translational studies in nonhuman primate models demonstrated that anti-LFA-1 used as an induction agent worked synergistically with belatacept in inhibiting graft rejection in a model of islet transplantation (Badell and Larsen, manuscript in preparation). Furthermore, investigator-initiated exploratory phase II studies using the anti-LFA-1 mAb, efalizumab have suggested efficacy in clinical islet cell transplantation (Larsen, submitted and Peter Stock and Andrew Poselt (University of California, San Francisco, personal communication). These data suggest that targeting LFA-1, and perhaps more broadly the adhesion pathways used by memory T cells to infiltrate grafted tissue, may be a potent method of attenuating memory T-cellmediated allograft rejection.
If donor-reactive memory T cells are able to infiltrate into the graft, what are the pathways necessary for their in-situ effector function? Schenk et al. [43] assessed the role of inducible costimulatory molecule (ICOS, CD278) in eliciting effector function from early graft-infiltrating memory T cells [43] . Their results revealed that while ICOS was not constitutively expressed on memory T cells, its expression was upregulated in situ following proliferation of memory T cells within the graft itself. Importantly, blockade of ICOS signaling via an anti-ICOS mAb resulted in a significant decrease in the early expression of IFN-g, perforin, granzyme B, and FasL mRNA within the graft [43] .
In addition, reagents, which block proteasome degradation and thereby inhibit NFkB nuclear translocation, are increasingly showing promise as inhibitors of donorreactive memory T-cell responses. For example, a recent in-vitro study demonstrated the ability of bortezomib, one such proteasome inhibitor, to suppress activation of resistant memory T cells in vitro [44] . Importantly, use of bortezomib was shown to preserve regulatory T-cell function while inhibiting the activation of donor-reactive memory T cells [44] .
Conclusion
Studies published within the last year have definitively demonstrated that not only is alloreactivity present within peripheral T-cell compartments of normal healthy individuals, but cross-reactivity between viralspecific T cells and allo-epitopes may in fact be a very common occurrence. Thus, the challenge facing the field over the next decade will be to define the functional phenotypes that exist within memory T-cell populations, as a result of the type and frequency of pathogen exposure, which results in a greater or lesser barrier to tolerance induction. For example, allo-cross-reactive memory in HLA-B08/B44 donor-recipient pairs is related to a latent pathogen (EBV), whereas the allo-cross-reactive memory found in HLA-DR3/DR4 combinations is related to a single or multiacute exposure to a cleared antigen (tetanus toxoid). Because these memory T cell type responses generated against these distinct types of exposures may pose different barriers and thus require different therapies, knowing the number and quality of these types of cells for individual patients may be important. Ultimately, one might foresee a strategy in which strength and type of immunosuppression could be tailored to fit the immunological history of a given transplant recipient in order to minimize nonimmune toxicities, maximize protective immunity, and prolong graft survival.
